Last reviewed · How we verify
Placebo (for Prednisolone)
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Control arm in Phase 3 clinical trial comparing prednisolone efficacy.
At a glance
| Generic name | Placebo (for Prednisolone) |
|---|---|
| Sponsor | Prof. Dominique de Quervain, MD |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials. Any observed effects result from expectation, conditioning, and the patient-clinician relationship rather than direct drug action. In this Phase 3 trial context, the placebo serves as a comparator to assess the true efficacy of prednisolone, a corticosteroid.
Approved indications
- Control arm in Phase 3 clinical trial comparing prednisolone efficacy
Common side effects
- Placebo effect (perceived symptom improvement)
- Nocebo effect (perceived adverse events)
Key clinical trials
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency (PHASE4)
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE3)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (PHASE3)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Prednisolone) CI brief — competitive landscape report
- Placebo (for Prednisolone) updates RSS · CI watch RSS
- Prof. Dominique de Quervain, MD portfolio CI